FRS2 (Ab-196) Antibody

What is the optimal method for validating FRS2 (Ab-196) antibody specificity?

Validating antibody specificity is crucial before experimental use. For FRS2 (Ab-196) antibody, the gold standard approach involves:

• Using cell lysates with known FRS2 expression (e.g., MCF-7, C2C12, PC-12 cell lines)

• Including positive controls (FGF-stimulated cells) and negative controls (untreated cells)

• Implementing peptide competition assays using the immunizing phosphopeptide

• Testing reactivity in FRS2 knockdown/knockout samples

• Using site-directed mutagenesis to create the FRS2 1F mutant (Y196F) to confirm epitope specificity

This multi-faceted validation approach ensures the antibody specifically recognizes phosphorylated Tyr196 of FRS2 rather than other phosphorylated residues or proteins.

What sample preparation techniques maximize phospho-FRS2 detection in Western blotting?

Phosphoprotein detection requires careful sample preparation:

• Rapid lysis in buffer containing phosphatase inhibitors (sodium orthovanadate, sodium fluoride, sodium pyrophosphate)

• Maintaining cold temperatures (4°C) throughout processing

• Using 8% SDS-PAGE gels for optimal separation (FRS2 appears at approximately 85 kDa, though calculated MW is 57-60 kDa)

• Transferring to PVDF membrane (preferred over nitrocellulose for phosphoproteins)

• Blocking with 5% BSA in TBST rather than milk (milk contains phosphoproteins that increase background)

• Including positive controls (FGF-stimulated cells) to confirm phosphorylation status

This protocol maximizes detection of transient phosphorylation events while minimizing background signal.

Why does FRS2 show a discrepancy between predicted (57 kDa) and observed (85 kDa) molecular weight?

This common observation reflects post-translational modifications:

The mobility shift occurs primarily because:

• FRS2 contains multiple phosphorylation sites (Y196, Y306, Y349, Y392, Y436)

• Each phosphorylation adds negative charge, reducing electrophoretic mobility

• Potential glycosylation or ubiquitination further increases apparent molecular weight

This mobility shift serves as a useful indicator of FRS2 activation status in experimental systems.

How can I distinguish between specific FRS2 (Tyr196) phosphorylation and cross-reactivity with other phosphotyrosine sites?

This critical distinction requires sophisticated experimental approaches:

• Parallel phospho-site analysis: Simultaneously probe replicate blots with antibodies against different FRS2 phospho-sites (Tyr196, Tyr436) to create phosphorylation profiles

• Mutant expression systems: Use cells expressing FRS2 point mutants:

  • 1F mutant (Y436F) - retains Tyr196 phosphorylation

  • 4F mutant (Y196F, Y306F, Y349F, Y392F) - lacks Grb2 binding sites

  • 5F mutant (all five tyrosines mutated) - negative control

• Sequential immunoprecipitation: First IP with general FRS2 antibody, then Western blot with phospho-specific antibody, comparing with direct Western blot results

These approaches together provide conclusive evidence of antibody specificity for the Tyr196 phosphorylation site.

What experimental design best demonstrates the functional significance of FRS2 Tyr196 phosphorylation versus other phosphorylation sites?

A comprehensive experimental design should include:

• Site-specific mutagenesis system:

  • Y196F single mutant

  • Y436F single mutant

  • Y196F/Y436F double mutant

  • WT FRS2 (positive control)

• Protein-protein interaction analysis:

  • Co-IP experiments to detect:

    • FRS2-Grb2 interaction (requires Tyr196)

    • FRS2-Shp2 interaction (requires Tyr436)

    • Ternary complex formation

• Functional cellular assays:

  • Proliferation assays

  • Migration assays

  • Differentiation markers

  • Angiogenesis assays (endothelial cell recruitment)

This design establishes both molecular mechanisms and biological outcomes dependent on specific phosphorylation events.

How should researchers interpret conflicting results between phospho-FRS2 (Tyr196) antibody staining and downstream ERK activation?

This common discrepancy requires systematic investigation:

• Temporal dynamics analysis:

  • Create a detailed time course (0, 5, 10, 30, 60, 120 min post-stimulation)

  • Simultaneously measure FRS2 Tyr196 phosphorylation and ERK activation

  • Different kinetics may explain apparent discrepancies

• Pathway cross-talk investigation:

  • Apply specific inhibitors:

    • MEK inhibitor (U0126) - blocks feedback phosphorylation

    • FGFR inhibitor (PD173074) - blocks initial activation

    • PI3K inhibitor - tests alternative pathway involvement

• Alternative adaptor protein assessment:

  • Examine other adaptor proteins (Shc, Gab1) that might compensate for FRS2

  • Consider receptor cross-activation (EGFR, PDGFR)

• Quantitative correlation analysis:

  FRS2 pTyr196 Level	pERK Level	Biological Context
  High	Low	Potential negative feedback or pathway inhibition
  Low	High	Alternative pathway activation
  Proportional	Proportional	Expected direct relationship

This systematic approach reveals whether discrepancies reflect biological regulation rather than technical artifacts.

What controls are essential for accurately interpreting phospho-FRS2 immunohistochemistry in tissue samples?

Immunohistochemistry with phospho-specific antibodies requires rigorous controls:

• Adjacent section controls:

  • Phospho-FRS2 (Tyr196) antibody

  • Total FRS2 antibody

  • Phosphatase-treated section (negative control)

• Biological context controls:

  • Normal tissue adjacent to pathological tissue

  • Tissues with known FRS2 activation status (positive controls)

  • FRS2-negative tissues (negative controls)

• Technical validation controls:

  • Peptide competition with phosphorylated and non-phosphorylated peptides

  • Secondary antibody-only control

  • Isotype control antibody

• Quantification methodology:

  • Use digital image analysis with consistent thresholding

  • Score both intensity and percentage of positive cells

  • Correlate with parallel Western blot results when possible

These controls ensure that observed staining represents genuine phospho-FRS2 rather than artifacts or non-specific binding.

How can phospho-FRS2 (Tyr196) antibodies be used to investigate cross-talk between FGFR and PDGFR signaling pathways?

This complex question requires multi-modal experimental approaches:

• Receptor activation sequence analysis:

  • Stimulate cells with:

    • FGF alone

    • PDGF alone

    • FGF + PDGF

    • Pre-treat with FGF, then PDGF (and vice versa)

  • Immunoprecipitate FGFR1 and blot for phospho-tyrosines

  • Immunoprecipitate PDGFRβ and blot for phospho-tyrosines

• Adaptor protein complex formation:

  • Co-immunoprecipitation of:

    • FRS2 and FGFR1

    • FRS2 and PDGFRβ

    • FGFR1 and PDGFRβ

  • Blot for phospho-FRS2 (Tyr196)

• Domain requirement mapping:

  • Express FGFR1 deletion mutants:

    • Lacking extracellular domain

    • Lacking intracellular domain

    • Lacking specific regions (e.g., juxtamembrane)

  • Assess impact on FRS2-PDGFRβ complex formation

This approach reveals how PDGFRβ induces tyrosine phosphorylation of FGFR1 and subsequent FRS2 recruitment/phosphorylation, clarifying signaling cross-talk mechanisms.

What is the significance of FRS2 amplification in cancer progression, and how can phospho-FRS2 antibodies inform potential therapeutic strategies?

FRS2 amplification appears in multiple cancer types with important implications:

This knowledge helps stratify patients and guide combination therapy selection, particularly for cancers with FRS2 amplification.

How can researchers design experiments to determine whether FRS2 activation in vascular smooth muscle cells occurs primarily through FGFR1 or through cross-activation by PDGFR?

This mechanistic question requires careful experimental design:

• Receptor-specific knockdown/inhibition:

  • siRNA against FGFR1

  • siRNA against PDGFRβ

  • siRNA against both receptors

  • Receptor-specific inhibitors (PD173074 for FGFR, imatinib for PDGFR)

• Complex formation dynamics:

  • Time-course immunoprecipitation of:

    • FGFR1 (blot for phospho-tyrosine, PDGFRβ, FRS2)

    • PDGFRβ (blot for phospho-tyrosine, FGFR1, FRS2)

    • FRS2 (blot for phospho-Tyr196, FGFR1, PDGFRβ)

• Downstream functional analysis:

  • Measure SMA and SM22α expression

  • Assess proliferation

  • Monitor ERK activation

  • Compare phenotypic changes with pathway activation patterns

Results from this experimental design would determine whether PDGF activates FRS2 through direct PDGFRβ interaction or by indirect FGFR1 transactivation, informing therapeutic targeting strategies for vascular pathologies.